35-40 mmHg (normal is no more than 20 mmHg) and a relatively preserved lung function (with low to normal arterial carbon dioxide tension) that cannot explain prominent dyspnoea and fatigue. The prevalence of out-of-proportion pulmonary hypertension in COPD is estimated to be very close to the prevalence of idiopathic pulmonary arterial hypertension. Cor pulmonale, defined as right ventricular hypertrophy and dilatation secondary to pulmonary hypertension caused by respiratory disorders, is common. More studies are needed to define the contribution of cor pulmonale to decreased exercise capacity in COPD. These studies should include improved imaging techniques and biomarkers, such as the B-type natriuretic peptide and exercise testing protocols with gas exchange measurements. The effects of drugs used in pulmonary arterial hypertension should be tested in chronic obstructive pulmonary disease patients with severe pulmonary hypertension. In the meantime, the treatment of cor pulmonale in chronic obstructive pulmonary disease continues to rest on supplemental oxygen and a variety of measures aimed at the relief of airway obstruction.">

Pulmonary hypertension in COPD

Chaouat A., Naeije R., Weitzenblum E.

Source: Eur Respir J 2008; 32: 1371-1385
Journal Issue: November
Disease area: Airway diseases, Pulmonary vascular diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Chaouat A., Naeije R., Weitzenblum E.. Pulmonary hypertension in COPD. Eur Respir J 2008; 32: 1371-1385

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Treatment of pulmonary hypertension in chronic obstructive pulmonary disease
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-48-0, page=313
Year: 2006

Pulmonary hypertension in patients with COPD
Source: Eur Respir Mon 2012; 57: 138-147
Year: 2012


Pulmonary hypertension in chronic obstructive pulmonary disease
Source: Eur Respir J 2003; 21: 892-905
Year: 2003



Relationship between exercise desaturation and pulmonary haemodynamics in COPD patients
Source: Eur Respir J 2004; 24 : 580-586
Year: 2004



Effects of Valsartan on pulmonary hemodynamics in patients with chronic obstructive pulmonary disease (COPD) and secondary pulmonary hypertension
Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies
Year: 2019


Impact of exacerbations on pulmonary arterial enlargement in patients with chronic obstructive pulmonary disease
Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment
Year: 2013

Systemic vascular function in chronic obstructive pulmonary disease
Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment
Year: 2013

Pulmonary hypertension: future therapies
Source: ISSN=1025-448x, ISBN=1-904097-31-6, page=84
Year: 2004

Fitness for flying and diving
Source: Annual Congress 2006 - PG3 - Update on occupational and environmental lung disease, including "bring your own cases" for interactive discussion
Year: 2006



Conclusion: treatment of pulmonary hypertension in COPD patients
Source: Annual Congress 2005 - COPD - pulmonary haemodynamics and gas exchange
Year: 2005

Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome
Source: Eur Respir J 2010; 35: 105-111
Year: 2010



Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis
Source: Eur Respir J 2012; 40: 93-100
Year: 2012



Systemic inflammation in chronic obstructive pulmonary disease in patients with pulmonary hypertension
Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities
Year: 2010

Influence of bronchodilators on pulmonary hypertension in patients with chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2003; 22: Suppl. 45, 427s
Year: 2003

Pulmonary arterial hypertension in the patients with chronic obstructive pulmonary disease
Source: Eur Respir J 2005; 26: Suppl. 49, 512s
Year: 2005

Effects of amlodipine on pulmonary haemodynamics in pulmonary hypertension (PH) secondary to chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2002; 20: Suppl. 38, 27s
Year: 2002

Gender-related differences in pulmonary hemodynamics in patients with end-stage COPD
Source: Annual Congress 2005 - COPD - pulmonary haemodynamics and gas exchange
Year: 2005


Systemic and pulmonary inflammation in chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2008 - Pathophysiology of COPD
Year: 2008


Pulmonary hypertension and exercise capacity in patients with severe chronic obstructive pulmonary disease
Source: Eur Respir J 2002; 20: Suppl. 38, 285s
Year: 2002